Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 -1.15%91 10-Year ROIIC % is 14.06 as of Dec. 2025. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$30.05 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 486 Healthcare Providers & Services companies, Raia Drogasil ranks better than 73.66% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Raia Drogasil's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 14.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Raia Drogasil's 10-Year ROIIC % or its related term are showing as below:
BSP:RADL3's 10-Year ROIIC % is ranked better than 73.66% of 486
companies
in the Healthcare Providers & Services industry
Industry Median: 3.445
vs BSP:RADL3: 14.06
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Raia Drogasil 10-Year ROIIC % Related Terms
Raia Drogasil 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil 10-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Raia Drogasil (BSP:RADL3) has a 10-Year ROIIC % of 14.06 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Raia Drogasil and its competitors. According to the industry distribution chart, Raia Drogasil ranks #128 out of 486 companies in the Healthcare Providers & Services industry, placing it in the top 26.3%.
Is Raia Drogasil's 10-Year ROIIC % too high?
Raia Drogasil's current 10-Year ROIIC % is 14.06. The Healthcare Providers & Services industry median 10-Year ROIIC % is 3.45. Raia Drogasil's value of 14.06 is 308.1% above this industry median. Based on the distribution chart, Raia Drogasil ranks #128 out of 486 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's 10-Year ROIIC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #128 out of 486 companies for 10-Year ROIIC %. This puts Raia Drogasil in the upper half of its industry. The industry median 10-Year ROIIC % is 3.45. Raia Drogasil's value of 14.06 is 308.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Healthcare Providers & Services company?
The median 10-Year ROIIC % among Healthcare Providers & Services companies is 3.45, based on 486 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current 10-Year ROIIC % of 14.06 is 308.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median 10-Year ROIIC % is 3.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current 10-Year ROIIC % is 14.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.05, compared to a current price of R$17.98 — trading 40.2% below its estimated fair value. The current 10-Year ROIIC % is 14.06 and 308.1% above the Healthcare Providers & Services industry median of 3.45. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current 10-Year ROIIC % is 14.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$17.98 is trading 40.2% below its estimated GF Value™ of R$30.05.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
10-Year ROIIC %: 14.06
GF Value™: R$30.05 vs. price of R$17.98 (40.2% below fair value)
Industry Position: 308.1% above the Healthcare Providers & Services median (#128 of 486)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
